Reducing Chemotherapy Toxicity with Pegylated Liposomal Doxorubicin
Author Information
Author(s): Eckes Jürgen, Schmah Oliver, Siebers Jan W, Groh Ursula, Zschiedrich Stefan, Rautenberg Beate, Hasenburg Annette, Jansen Martin, Hug Martin J, Winkler Karl, Pütz Gerhard
Primary Institution: University Medical Center Freiburg
Hypothesis
Can extracorporeal elimination of pegylated liposomal doxorubicin reduce toxicity during chemotherapy?
Conclusion
Extracorporeal elimination of pegylated liposomal doxorubicin by double filtration plasmapheresis is safe and efficient, reducing major side effects.
Supporting Evidence
- 62% of circulating pegylated liposomal doxorubicin was eliminated during treatment.
- Reduction in tumor size greater than 30% was observed in 10 out of 12 patients with breast cancer.
- Only one grade 2 side effect was reported during the trial.
Takeaway
This study shows that a special treatment can help remove some of the harmful medicine from the body during cancer treatment, making it safer.
Methodology
Patients received pegylated liposomal doxorubicin and underwent double filtration plasmapheresis to eliminate circulating liposomes.
Limitations
The study had a small sample size and was not randomized.
Participant Demographics
Patients aged 39 to 67, with 12 treated for breast cancer and 3 for recurrent ovarian cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website